ASAP-NL- Atorvastatin vs. Simvastatin on Atherosclerosis Progression Study

Principal contacts

Eric de Groot - Imagelabonline & Cardiovascular, Eindhoven and Lunteren, the Netherlands

Study design

The Atorvastatin vs. Simvastatin on Atherosclerosis Progression Study (ASAP-NL) is a two-arm clinical trial based at two clinical centres: at the University Medical Center Nijmegen and the Academic Medical Centre Amsterdam. The principal aim of the trial was to investigate the effect of Simvastatin (40mg/day) versus Atorvastatin (80mg/day) on atherosclerosis in patients with familial hypercholesterolaemia. Individuals were eligible for inclusion if they were aged between 30 and 70 years with familial hypercholesterolaemia and with a mean intima-media thickness of at least 0.7mm at the common carotid artery  or at least 0.9mm at the carotid bulb. The ethics committees of the centres approved the protocol and written informed consent was obtained from participating individuals.


Key publications

Rationale, Design and Baseline Characteristics of a Clinical Trial Comparing the Effects of Robust vs Conventional Cholesterol Lowering and Intima Media Thickness in Patients with Familial Hypercholesterolaemia: The Atorvastatin versus Simvastatin on Atherosclerosis Progression (ASAP) Study. Clin Drug Investig. 2000;20(2):67-79

Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet. 2001 Feb 24;357(9256):577-81